TY - JOUR
T1 - Prevalence and trends in persistent symptoms following COVID-19 in Japan
T2 - A nationwide cross-sectional survey
AU - Takamatsu, Akane
AU - Honda, Hitoshi
AU - Miwa, Toshiki
AU - Tabuchi, Takahiro
AU - Taniguchi, Kiyosu
AU - Shibuya, Kenji
AU - Tokuda, Yasuharu
N1 - Publisher Copyright:
© 2024 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control
PY - 2024/8
Y1 - 2024/8
N2 - Introduction: Even during the endemic phase of the COVID-19 pandemic, the impact of persistent symptoms on patients and healthcare systems remains significant. Thus, a more comprehensive understanding of these symptoms is essential. Methods: Using data from the Japan Society and New Tobacco Internet Survey conducted in February 2023, this cross-sectional study investigated the prevalence of, and changes in, persistent COVID-19 symptoms. Results: In total, 21,108 individuals responded to the survey. Of these, 29.1 % (6143) had a history of COVID-19. Our analysis found that arm/leg/joint pain (adjusted odds ratio [aOR]: 1.17; 95 % confidence interval [95 % CI]: 1.03–1.33), back pain (aOR: 1.13; 95 % CI: 1.01–1.27), chest pain (aOR: 1.53; 95 % CI: 1.20–1.96), malaise (aOR: 1.14; 95 % CI: 1.02–1.28), loss of taste (aOR: 2.55; 95 % CI: 1.75–3.72), loss of smell (aOR: 2.33; 95 % CI: 1.67–3.26), memory impairment (aOR: 1.27; 95 % CI: 1.04–1.56), and cough (aOR: 1.72; 95 % CI: 1.38–2.13) were independently associated with a history of COVID-19 contracted more than two months but less than six months previously. Further, back pain (aOR: 1.24; 95 % CI: 1.04–1.47) and loss of taste (aOR: 2.28; 95 % CI: 1.24–4.21) showed independent association with COVID-19 contracted more than 12 months previously. Conclusions: Various symptoms were independently associated with a history of COVID-19. While most patients tend to recover within a year after contracting COVID-19, certain symptoms, such as back pain and loss of taste, persist longer than a year, underscoring public health concerns and emphasizing the need for health care services to support patients suffering from persistent symptoms.
AB - Introduction: Even during the endemic phase of the COVID-19 pandemic, the impact of persistent symptoms on patients and healthcare systems remains significant. Thus, a more comprehensive understanding of these symptoms is essential. Methods: Using data from the Japan Society and New Tobacco Internet Survey conducted in February 2023, this cross-sectional study investigated the prevalence of, and changes in, persistent COVID-19 symptoms. Results: In total, 21,108 individuals responded to the survey. Of these, 29.1 % (6143) had a history of COVID-19. Our analysis found that arm/leg/joint pain (adjusted odds ratio [aOR]: 1.17; 95 % confidence interval [95 % CI]: 1.03–1.33), back pain (aOR: 1.13; 95 % CI: 1.01–1.27), chest pain (aOR: 1.53; 95 % CI: 1.20–1.96), malaise (aOR: 1.14; 95 % CI: 1.02–1.28), loss of taste (aOR: 2.55; 95 % CI: 1.75–3.72), loss of smell (aOR: 2.33; 95 % CI: 1.67–3.26), memory impairment (aOR: 1.27; 95 % CI: 1.04–1.56), and cough (aOR: 1.72; 95 % CI: 1.38–2.13) were independently associated with a history of COVID-19 contracted more than two months but less than six months previously. Further, back pain (aOR: 1.24; 95 % CI: 1.04–1.47) and loss of taste (aOR: 2.28; 95 % CI: 1.24–4.21) showed independent association with COVID-19 contracted more than 12 months previously. Conclusions: Various symptoms were independently associated with a history of COVID-19. While most patients tend to recover within a year after contracting COVID-19, certain symptoms, such as back pain and loss of taste, persist longer than a year, underscoring public health concerns and emphasizing the need for health care services to support patients suffering from persistent symptoms.
KW - COVID-19
KW - Long COVID
KW - National survey
KW - Persistent symptoms
KW - Post COVID-19 condition
UR - http://www.scopus.com/inward/record.url?scp=85185924003&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85185924003&partnerID=8YFLogxK
U2 - 10.1016/j.jiac.2024.02.008
DO - 10.1016/j.jiac.2024.02.008
M3 - Article
C2 - 38346670
AN - SCOPUS:85185924003
SN - 1341-321X
VL - 30
SP - 725
EP - 733
JO - Journal of Infection and Chemotherapy
JF - Journal of Infection and Chemotherapy
IS - 8
ER -